Porownywarka

Melanotan I vs GHK-Cu side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

Melanotan IGHK-Cu

Udostępnij porównanie peptydów

Wlasciwosc	Melanotan I	GHK-Cu
Kategoria	Skóra i włosy	Skóra i włosy
Znany tez jako	Afamelanotide, Scenesse, MT-1, CUV1647, [Nle4, D-Phe7]-alpha-MSH, NDP-MSH	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA Approved (2019) - Erythropoietic Protoporphyria Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Skin tanning, photoprotection, sun sensitivity disorders	Skin rejuvenation, wound healing, hair growth, anti-aging
Jak dziala	Afamelanotide is described as an MC1R agonist acting on melanocytes. Activation of this melanocortin receptor promotes eumelanin production, which the source connects with photoprotection in EPP. The analog differs from native alpha-MSH at positions 4 and 7, changes reported to improve receptor binding and metabolic stability. The source also states that, compared with Melanotan II, Melanotan I is not primarily framed as an appetite or sexual-function peptide because of its relative MC1R selectivity.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typowe dawkowanie	500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) · Daily during loading (1-2 weeks), then 1-2x weekly maintenance · Injected subcutaneously like MT-II	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Dawkowanie z badań	16 mg subcutaneous implant · Long-term / as needed before sun season · Subcutaneous implant (not injection)	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typowy czas trwania	Long-term / as needed before sun season	Varies by application
Podanie	Subcutaneous implant (not injection)	Subcutaneous injection or topical application
Timing	Evening or before sun exposure With or without food	Evening for skin or recovery contexts With or without food
Poziom dowodów	Zatwierdzone przez FDA	Badania kliniczne
Mozliwe skutki uboczne	Nausea (Reported as common in the source side-effect list.) Skin darkening (Listed as an intended effect.) Headache (Reported side effect; no severity qualifier supplied.) +3 więcej Fatigue (Reported side effect; no severity qualifier supplied.) Injection site reactions (Reported administration-site effect; source also distinguishes the approved implant from community injection use.) Known safety-profile context in FDA-approved use (The source lists FDA-approved status with known safety profile as safety context rather than a discrete adverse event.)	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 więcej Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Podsumowanie researchu	The source describes human clinical evidence in erythropoietic protoporphyria, including two multicenter randomized, double-blind, placebo-controlled trials reported in 2015 by Langendonk et al. in the New England Journal of Medicine. Across EU and US sites, 168 people with EPP received either a 16 mg implant or placebo every 60 days. Reported outcomes included longer pain-free sunlight exposure, fewer phototoxic reactions and better disease-specific quality-of-life measures; the US trial example cited median pain-free sunlight time of 69.4 hours versus 40.8 hours. Long-term observational data are described as supporting ongoing benefit with an acceptable safety profile. The source emphasizes that the approval is limited to EPP and that unregulated injectable Melanotan products are not the controlled clinician-administered implant.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
Referencje	New England Journal of Medicine PubMed Central +3 więcej WikipediaAfamelanotide DermNet NZAfamelanotide PubMed	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Melanotan I

GHK-Cu

Kategoria

Skóra i włosy

Znany tez jako

Afamelanotide, Scenesse, MT-1, CUV1647, [Nle4, D-Phe7]-alpha-MSH, NDP-MSH

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA Approved (2019) - Erythropoietic Protoporphyria

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Skin tanning, photoprotection, sun sensitivity disorders

Skin rejuvenation, wound healing, hair growth, anti-aging

Jak dziala

Afamelanotide is described as an MC1R agonist acting on melanocytes. Activation of this melanocortin receptor promotes eumelanin production, which the source connects with photoprotection in EPP. The analog differs from native alpha-MSH at positions 4 and 7, changes reported to improve receptor binding and metabolic stability. The source also states that, compared with Melanotan II, Melanotan I is not primarily framed as an appetite or sexual-function peptide because of its relative MC1R selectivity.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typowe dawkowanie

500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) · Daily during loading (1-2 weeks), then 1-2x weekly maintenance · Injected subcutaneously like MT-II

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Dawkowanie z badań

16 mg subcutaneous implant · Long-term / as needed before sun season · Subcutaneous implant (not injection)

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typowy czas trwania

Long-term / as needed before sun season

Varies by application

Podanie

Subcutaneous implant (not injection)

Subcutaneous injection or topical application

Timing

Evening or before sun exposure

With or without food

Evening for skin or recovery contexts

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Badania kliniczne

Mozliwe skutki uboczne

Nausea (Reported as common in the source side-effect list.)
Skin darkening (Listed as an intended effect.)
Headache (Reported side effect; no severity qualifier supplied.)

+3 więcej

Fatigue (Reported side effect; no severity qualifier supplied.)
Injection site reactions (Reported administration-site effect; source also distinguishes the approved implant from community injection use.)
Known safety-profile context in FDA-approved use (The source lists FDA-approved status with known safety profile as safety context rather than a discrete adverse event.)

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 więcej

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Podsumowanie researchu

The source describes human clinical evidence in erythropoietic protoporphyria, including two multicenter randomized, double-blind, placebo-controlled trials reported in 2015 by Langendonk et al. in the New England Journal of Medicine. Across EU and US sites, 168 people with EPP received either a 16 mg implant or placebo every 60 days. Reported outcomes included longer pain-free sunlight exposure, fewer phototoxic reactions and better disease-specific quality-of-life measures; the US trial example cited median pain-free sunlight time of 69.4 hours versus 40.8 hours. Long-term observational data are described as supporting ongoing benefit with an acceptable safety profile. The source emphasizes that the approval is limited to EPP and that unregulated injectable Melanotan products are not the controlled clinician-administered implant.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

Referencje

New England Journal of Medicine PubMed Central

+3 więcej

WikipediaAfamelanotide DermNet NZAfamelanotide PubMed

PubMed PubMed

+1 więcej

PubMed

Pełny profil

Zobacz szczegóły